Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients With Surgically Resected Glioblastoma (GBM) or Astrocytoma With a Molecular Signature of Unmethylated Glioblastoma

NCT05938387 is registered in ClinicalTrials.gov with CureVac as lead sponsor.

NCT NCT05938387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05938387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Finding Study to Evaluate Safety and Tolerability of CVGBM in Patients With Surgically Resected Glioblastoma (GBM) or Astrocytoma With a Molecular Signature of Unmethylated Glioblastoma
Lead sponsor
CureVac
Phase
Phase 1
Overall status
Completed
Start date
June 1, 2023
Completion date
February 2, 2026
Enrollment
37 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma